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Circulating cancer cells can putatively colonize distant organs to form
metastases or to reinfiltrate primary tumors themselves through a
process termed “tumor self-seeding.” Here we exploit this biological
attribute to deliver tumor necrosis factor alpha (TNF), a potent anti-
tumor cytokine, directly to primary and metastatic tumors in a mech-
anism that we have defined as “tumor self-targeting.” For this
purpose, we genetically engineered mouse mammary adenocarci-
noma (TSA), melanoma (B16-F10), and Lewis lung carcinoma cells
to produce and release murine TNF. In a series of intervention trials,
systemic administration of TNF-expressing tumor cells was associ-
ated with reduced growth of both primary tumors and metastatic
colonies in immunocompetent mice. We show that these malignant
cells home to tumors, locally release TNF, damage neovascular endo-
thelium, and induce massive cancer cell apoptosis. We also demon-
strate that such tumor-cell–mediated delivery avoids or minimizes
common side effects often associated with TNF-based therapy, such
as acute inflammation and weight loss. Our study provides proof of
concept that genetically modified circulating tumor cells may serve
as targeted vectors to deliver anticancer agents. In a clinical context,
this unique paradigm represents a personalized approach to be
translated into applications potentially using patient-derived circulat-
ing tumor cells as self-targeted vectors for drug delivery.
engineered tumor cells | tumor necrosis factor | vascular damaging agent |
endothelial cells | apoptosis
Ahallmark of cancer is the dissemination of tumor cells intothe vascular system and colonization of distant organs to form
metastatic foci. Recent studies showed that circulating cancer cells
can traffic from primary or metastatic lesions to the peripheral blood
and then back to their tumor of origin through a process termed
“self-seeding” (1, 2). This process is proposed to mediate cancer
progression by recruiting circulating tumor cells capable of surviving
under harsh conditions in the bloodstream, thereby promoting both
primary tumor growth and secondary metastatic dissemination (1, 3).
Such homing properties may be facilitated by the presence of blood
vessels with altered vascular endothelial barrier function in tumors
(2, 4) and by the presence of a favorable tumor microenvironment (1).
This unique concept provides a rationale for exploiting cancer
cells (5) as vehicles to deliver therapeutic agents to tumors, referred
to hereafter as (“tumor self-targeting”). Indeed, oncolytic viruses
incorporated within cancer cells have been shown to target lung
metastases, being protected from circulating antibodies (5–7). Thus,
we reasoned that “armed” tumor cells genetically manipulated to
express anticancer cytokines and subsequently administered into the
bloodstream should be able to deliver such factors focally to both
primary andmetastatic lesions as a therapeutic strategy. This delivery
method may circumvent toxicity and activation of systemic coun-
terregulatory mechanisms, which currently cause major limitations
for cytokine biotherapy against cancer (8). To address this hypothesis
experimentally, we engineered murine mammary adenocarcinoma,
melanoma, and lung carcinoma cells to produce and release tumor
necrosis factor alpha (TNF), a cytokine that damages the tumor
vascular endothelia and has anticancer activity (9–11). The rationale
for choosing this cytokine is based on our previous work that dem-
onstrated ligand-based delivery of extremely low concentrations of
TNF to tumor blood vessels markedly inhibits tumor growth in
various xenograft (12–14) experimental mouse tumor models, and in
a variety of native tumors in pet dogs (15). We show that systemic
administration of several types of TNF-expressing cancer cells in
syngeneic and nonsyngeneic tumor-bearing mice inhibits the growth
of primary and metastatic cancers. We provide evidence that this
effect is due to specific targeting to tumors, whereby injected cells
accumulate and locally release TNF, resulting in tumor vasculature
damage and tumor cell apoptosis.
Results
TNF-Expressing Tumor Cells: In Vitro and in Vivo Characterization. To
exploit the concept of tumor self-targeting for the delivery of TNF
to primary and metastatic tumor sites, we transduced murine TSA
mammary adenocarcinoma tumor cells, B16-F10 melanoma cells,
and Lewis lung cancer (LLC) cells with a lentiviral vector con-
taining the murine TNF gene (pLenti-mtnf). The amount of bio-
active TNF released in the supernatants of lentivirus-transduced
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cells was evaluated with a sensitive cell-based cytolytic assay
(Fig. 1A). Through this approach, we generated tumor cell pop-
ulations that produce levels of TNF that span three to four orders
of magnitude, hereafter defined as: TSAtnf low and TSAtnf [91.5 and
153 femtograms (fg) per cell per day, respectively], B16-F10tnf low
and B16-F10tnf (2.7 and 23.5 fg per cell per day, respectively), and
LLCtnf low and LLCtnf (0.015 and 0.178 fg per cell per day, re-
spectively). TNF production did not affect the proliferation index
of transduced cells relative to the corresponding parental cells
(Fig. 1B). Furthermore, escalating doses of exogenous, recombi-
nant TNF (0.5–500 ng/mL) did not exert cytotoxic effects on
parental tumor cells (Fig. 1C). These results demonstrate that
TNF does not affect tumor cell growth and viability in vitro.
Next, the tumorigenic and metastatic potential of TNF-expressing
tumor cells was investigated by administering TNF-expressing TSA,
B16-F10, or LLC cells to immunocompetent syngeneic mice, either
s.c. or i.v. TNF expression levels correlated with reduced growth
rates of all s.c.-implanted tumors (Fig. 1D), as well as with the
number of metastatic colonies in the lungs (Fig. 1E), compared with
tumor numbers produced by the parental tumor cells. Of note, TNF-
expressing TSA tumor cells did not grow at all, presumably as a
consequence of the highest levels of secreted TNF (Fig. 1A). Fur-
thermore, these mice were protected from subsequent s.c. challenges
with parental TSA cells (Fig. 1F). Taken together, these results
demonstrate that TNF secreted by tumor cells has an antitumor
effect on both primary and metastatic tumors in vivo.
TNF-Expressing Cancer Cells Inhibit the Growth of Primary Tumors
and Lung Colonies in Mice. To evaluate the potential therapeutic
application of TNF-expressing tumor cells, we investigated the
Fig. 1. In vitro and in vivo growth of genetically engineered TSA, B16-F10, and LLC cells that express varying amounts of TNF. (A) Amounts of bioactive TNF
released per cell per day into the supernatant by different populations of TSA, B16-F10, and LLC cells transduced with pLenti-mTNF (TSAtnf, B16-F10tnf, and
LLCtnf), as measured by a cytolytic assay. Each experiment was performed in triplicate, and repeated three times. Representative experiments are shown (SEM)
and depicted ± SEM). (B) In vitro proliferation of transduced and nontransduced tumor cells as evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) staining. Two experiments were performed in quadruplicate. One representative experiment is shown (mean ± SEM). (C) Effect of
TNF on TSA, B16-F10, and LLC cell viability analyzed by a cytotoxicity assay. (D) Tumorigenic properties of transduced and nontransduced cells. Mice were
administered s.c. with parental or TNF-producing TSA, B16-F10, or LLC cells (Tc, tumor cell). The growth of s.c. tumors was monitored by measuring tumor
volumes with a caliper at serial time points. (E) Colonies of transduced and nontransduced cells. Parental or TNF-producing TSA, B16-F10, or LLC cells were
injected i.v., mice were killed, and the lungs were inspected for the presence of metastasic foci. The numbers of colonies per lung or lung weights are shown
(mean ± SEM; n = 3–6 as indicated). Dashed line in the LLC bars indicates the average weight of normal lungs. (F) TSAtnf cells implanted s.c. in syngeneic mice
protect against further challenge with TSA cells. BALB/c mice were injected s.c. with TSAtnf (4 × 105 cells per mouse). No visible tumor formation occurred.
Thirty days later, TSA cells were implanted s.c. and tumor growth was monitored. Mice in which TSAtnf cells did not grow were also unaffected by the
subsequent challenge with TSA cells. Experimental schedule and tumor volumes (mean ± SEM) of one representative experiment are shown (n = 3–4 as
indicated). Three experiments were performed. *P < 0.05; ***P < 0.001 by Student’s t test, two tailed.
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effect of their systemic administration on the growth of established
primary tumors. We administered TSAtnf, B16-F10tnf, or LLCtnf
(i.v., three times) to syngeneic mice bearing s.c. implanted TSA, B16-
F10, or LLC tumors, respectively. Although TSAtnf, B16-F10tnf, or
LLCtnf produce widely ranging levels of TNF in vitro, i.v. adminis-
tration inhibited tumor growth by 50%, 65%, or 55%, respectively
(Fig. 2A). When we compared i.v. and s.c. routes of administration,
we observed that s.c. injection of TSAtnf cells into the contralateral
Fig. 2. Systemic cell-dose–dependent administration of TNF-expressing cells reduces the growth of s.c. tumors and the number of lung colonies in syngeneic and
nonsyngeneic models. (A) Effect of i.v. administration of TSAtnf, B16-F10tnf, or LLCtnf cells on the growth of s.c. TSA, B16-F10, or LLC tumors, respectively. A general
treatment schedule is shown (Tc, tumor cell; Tctnf, TNF-expressing tumor cells). Treatments started when tumor volumes reached ∼50 mm3. Tumor volumes (mean ±
SEM) from one representative experiment are shown (n = 4–8 as indicated). Two experiments were performed. (B) Effect of i.v. administration of TSAtnf, B16-F10tnf,
or LLCtnf on the number of colonies in the lungs of mice receiving i.v. TSA, B16-F10, or LLC cells, respectively. A general treatment schedule is shown. Treatments
started 7 d after i.v. administration of parental tumor cells. The number of colonies per lung (mean ± SEM; cumulative data from two experiments, n = 4–5 each) or
lung weight (mean ± SEM; one experiment, n = 4) are shown. (C, Left) Experimental schedule. (Center) Effect of three i.v. injections of 0, 1.85, 7.5, or 30 × 104 TSAtnf
cells on s.c. TSA tumors (n = 4–5, mean ± SEM). (Right) Effect of three i.v. injections of TSAtnf, or TSAtnf low, or TSA cells (7.5 × 104 cells per mouse) on s.c. TSA tumors.
Tumor volumes (mean ± SEM) are shown (n = 5). (D) Effect of i.v. administration of TSAtnf cells (arrows, 7.5 × 105) on the growth of B16-F10 tumors implanted s.c in
C57/BL6 mice (syngeneic with B16-F10, nonsyngeneic for TSA cells). Tumor volumes (mean ± SEM) are shown as cumulative results from two different experiments
(n = 3 each). (E) Evaluation of metastatic colonies following B16-F10tnf or TSAtnf i.v. injection in C57BL/6 mice (syngeneic for B16-F10 cells, nonsyngeneic for TSA cells).
Lungs were inspected for the presence of visual colonies at day 26 (n = 4, mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001 by Student’s t test, two tailed.











flank was unable to inhibit growth of the established s.c.-implanted
TSA tumor (Fig. S1A); in contrast, when TSAtnf cells were i.v. ad-
ministered, tumor growth of the established s.c.-implanted TSA tu-
mor was inhibited (Fig. S1B). This intriguing observation indicates
that the presence of TNF-expressing tumor cells in the vascular
circulation is critical for antitumor activity of the primary tumor.
To determine whether i.v.-administered TNF-expressing
cells would limit the growth of metastatic tumors, mice were
injected i.v. with TSA, B16-F10, or LLC parental tumor cells
and allowed to circulate and form lung colonies. One week
later, tumor-bearing mice were injected i.v. with TSAtnf, B16-
F10tnf, or LLCtnf tumor cells, respectively. Tumor-bearing
mice were killed to quantify the number of metastatic lung
colonies at 14 (TSA), 11 (B16-F10), or 28 (LLC) days, post-
injection of each of the three tumor types. Remarkably, the
number of metastatic colonies in the lungs of mice treated with
TNF-expressing tumor cells was significantly reduced com-
pared with control mice (Fig. 2B). Taken together, these data
demonstrate that systemic administration of TNF-expressing
cancer cells partially inhibits the growth of tumors in the pri-
mary and metastatic settings.
The Therapeutic Effect of Circulating TSAtnf Cells Is Dependent on the
Number of TNF-Expressing Cells. To characterize the antitumor
effects of circulating TNF quantitatively, we next analyzed
whether this effect is dependent on (i) the number of TNF-
expressing cells or (ii) the amount of TNF. For these refinement
studies, we chose the TSA cell line because its tumor-homing
properties have been extensively characterized (2) and, the range
of expressed TNF was higher in these cells than in the B16-F10
or LLC cells. When we i.v. administered 1.85 × 104, 7.5 × 104, or
30 × 104 TSAtnf cells per mouse (at 153 fg per cell per day) to
mice bearing s.c.-implanted TSA tumors, we observed a cell-
number–dependent antitumor effect (Fig. 2C, Left graph). Moreover,
when an equal number of cells (7.5 × 104 cells per mouse) was in-
jected that express either low or high TNF (91.5 or 153 fg per cell
per day), we found no significant difference in their antitumor
activity (Fig. 2C, Right graph). These independent results are in line
with the data shown in Fig. 2A and indicate that the antitumor
effect of TNF-expressing cells does not require a large concen-
tration of TNF to inhibit tumor growth. Rather, tumor growth
inhibition is proportional to the number of TNF-expressing tumor
cells administered.
Irradiated TSAtnf Cells Partially Inhibit Tumor Growth. To assess
whether TSAtnf cells retained any antitumor activity in the absence
of proliferation, we irradiated them to induce cell cycle arrest (16).
Irradiation reduced the cell proliferation index without affecting
TNF production (Fig. S2A). When these cells were injected into
mice bearing s.c. TSA tumors, they showed a nonsignificant tumor
volume reduction, indicating the importance of cell proliferation to
support their therapeutic effect (Fig. S2B).
Systemic Administration of TSAtnf Inhibits the Growth of B16-F10
Tumors. Given that cross-seeding between heterotypic tumors
(melanoma and mammary tumors) is experimentally established
(1), we next investigated whether the therapeutic effect of TSAtnf
cells would be effective in a nonsyngeneic setting using B16-F10
tumors. TSAtnf cells (derived from BALB/c mice) were adminis-
tered i.v. into C57BL/6 mice bearing s.c.-implanted B16-F10 tu-
mors. We observed antitumor effects similar to those obtained with
the syngeneic models described above (Fig. 2D). As predicted,
because TSAtnf cells were administered into nonsyngeneic mice,
they were eventually rejected by the host and did not establish lung
colonies (Fig. 2E). Nevertheless, our results demonstrated that
TSAtnf cells circulate for a sufficient period to exert a therapeutic
effect. Collectively these results indicate a potential antitumor
approach to deliver cytokines by transducing host tumor cells.
TSAtnf Cells Home to Subcutaneous TSA Tumors and Locally Release
TNF. To quantify tumor homing and local release of TNF by
circulating TNF-expressing cells, we first administered TSA
or TSAtnf cells i.v. into mice bearing s.c. TSA tumors (Fig. 3A).
The growth rate of TSA tumors was significantly lower in
Fig. 3. TSAtnf cells home to TSA tumors and locally release within the pri-
mary tumor. (A) Experimental schedule. (B–D) Effect of i.v. administration of
TSAtnf or TSA cells to TSA tumor-bearing mice (s.c.) on (B) tumor volume,
(C) tumor weight, and (D) animal weight (n = 7–9, as indicated; mean ± SEM).
(E) Quantification of pLENTI-mtnf DNA, by semiquantitative PCR, in tumors and
in the blood after i.v. administration of TSA or TSAtnf cells (n = 6). (F) Quanti-
fication of TNF levels by ELISA in tumors and in the peripheral blood of mice
after i.v. administration of TSA or TSAtnf cells (n = 7–9, as indicated). *P < 0.05;
**P < 0.01 by Student’s t test, two tailed.
Fig. 4. TSAtnf cells induce endothelial and tumor apoptosis. (A) Effect of i.v.
injection of TSA or TSAtnf cells on endothelial cell apoptosis in TSA tumors (s.c.).
Immunofluorescent costaining for cCasp3 and CD31 in tumor tissue sections
obtained 1 d after treatment. The whole section was inspected (one section per
tumor, five tumors per group; mean ± SEM). (B) Effect of i.v. administration of
TSA or TSAtnf cells on cell apoptosis in TSA tumors (s.c.) 2 d after treatment, by
immunofluorescence analysis of cCasp3 in tumor tissue sections. Positive cCasp3
areas (mean ± SEM) are shown as percentage of the total area (20 images per
section, one section per tumor, three tumors per group). *P < 0.05; **P < 0.01
by Student’s t test, two tailed.
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TSAtnf-treated mice (Fig. 3 B and C); a result consistent with our
hypothesis. It is noteworthy that injected TSAtnf cells did not cause
weight loss in TSA tumor-bearing animals (Fig. 3D), which is a
typical toxic side effect caused by conventional therapeutic doses
of TNF (13). The presence of TSAtnf cells was analyzed both in
the peripheral blood (at days 1, 2, and 4 after systemic adminis-
tration) and in tumors (at day 4) by semiquantitative PCR with
primers to amplify a sequence in pLenti-mtnf–transduced cells
that is absent in the normal mouse genome. We also analyzed
the circulating levels and intratumor concentrations of TNF by
ELISA (DuoSet, R&D Systems). Notably, pLenti-mtnf DNA was
detected in the circulation at day 1 after TSAtnf administration,
but not at days 2 or 4 (Fig. 3E, Left), data indicating that TSAtnf
cells are cleared from the systemic circulation. In contrast, PCR
analysis revealed an accumulation of pLenti-mtnf DNA in TSA
tumors excised at day 4, confirming that TSAtnf cells home to the
tumor, thus corroborating the tumor self-seeding hypothesis (Fig.
3E, Right) (2). TNF was not detected in the circulation by ELISA
even when TSAtnf cells were present (Fig. 3F, Left). By contrast,
increased levels of TNF were detected at day 4 in tumors of mice
injected with TSAtnf cells compared with mice injected with TSA
cells (Fig. 3F, Right). These experimental findings support our in-
terpretation that TSAtnf cells are capable of homing to tumors and
locally releasing TNF. Furthermore, the absence of detectable
TNF in the peripheral blood and the lack of weight loss in mice
treated with TSAtnf cells strongly indicate that the therapeutic ef-
fect is mediated by local cellular production of TNF and not by
systemic release from circulating TSAtnf cells.
Systemic Administration of TSAtnf Cells Induces Vascular Endothelial
Damage and Causes Apoptosis in Subcutaneous Tumors. To characterize
the mechanism underlying the antitumor activity of TNF-expressing
cells, we investigated the effect of TSAtnf cells on the viability of
endothelial and tumor cells in s.c. TSA tumors. To this end, we
evaluated the presence of apoptotic endothelial cells with antibodies
against cleaved caspase 3 (cCasp3) (a marker of apoptosis) and
CD31 (a surface marker of endothelial cells) in tumor tissue sections
by coimmunofluorescence staining 1 d after TSAtnf injection. A
significant increase in apoptotic CD31-expressing cells in TSAtnf-
treated mice was observed (Fig. 4A), revealing the presence of vas-
cular endothelial cell damage. To assess whether this vascular
damage could cause secondary apoptotic responses in tumors, we
analyzed cCasp3 expression 2 d after TSAtnf administration. TSAtnf-
treated tumors had larger apoptotic areas compared with TSA-
treated tumors (Fig. 4B), consistent with our experimental hypothesis
that tumor growth inhibition is dependent on number of TNF-
expressing cells rather than on the amount of TNF expressed per
cell. These results indicate that, after homing to tumors, TSAtnf cells
release TNF, which in turn, causes local vascular damage, leading to
tumor cell apoptosis.
Systemic Administration of TSAtnf Cells Does Not Affect Recruitment
of CD45+ Cells in Tumors. Because TNF is an inflammatory cyto-
kine (10), we evaluated whether treatment with TSAtnf cells
would affect the inflammatory infiltrates in TSA tumors by
FACS analysis. After evaluating different populations of CD45+
cells, including lymphocytes, dendritic cells, and monocytes
(CD8+, CD4+, CD11c+, Gr1+CD11b−, Gr1+CD11b+, and Gr1−
CD11b+), we found no significant differences between controls
or mice treated with TSAtnf, except for a modest increase of
CD4+ T cells (Fig. S3). These results confirm that the release of
TNF by tumor cells does not change the composition of in-
filtrating inflammatory cells into s.c.-implanted TSA tumors
under our experimental conditions.
Discussion
The present study shows that systemic administration of genetically
engineered tumor cells that produce and release TNF—a very
potent pleiotropic cytokine (10, 11)—inhibits the growth of pri-
mary and metastatic tumors in three different murine models:
TSA, melanoma (B16-F10), and LLC. These TNF-expressing cells
home to tumors, locally release TNF, induce vascular endothelial
cell damage, and subsequently cause tumor cell apoptosis, a bi-
ological phenomenon defined here as “tumor self-targeting.” Our
preclinical findings support a provocative paradigm in which tumor
cells manipulated ex vivo and administered into the peripheral
bloodstream may serve as carriers for the therapeutic delivery of
bioactive cytokines and potentially additional proteins, as tumor-
targeted agents.
The efficacy of cytokines in cancer therapy is often reduced by
their toxicity and counterregulatory mechanisms. Such limitations
may be partially overcome in the case of TNF and IFNγ by a ligand-
directed strategy based on cytokine fusion with peptides or anti-
bodies selective for unique surface receptors on tumor endothelial
or epithelial cells (12–15, 17). However, administration of targeted
TNF or IFNγ close to the maximum tolerated dose still leads to
systemic activation of counterregulatory mechanisms that reduce
their potential anticancer activity (12). The approach described
here represents an alternative and/or additional strategy to deliver
cytokines to tumors, which is based on living cells and offers several
advantages. First, tumor cells can be engineered to produce and
release multiple cytokines into the tumor microenvironment, thus
favoring local synergistic interactions that can be achieved with
much lower levels of each cytokine. For example, a coexpression of
EMAP-II or IFNγ, two cytokines known to enhance TNF activity,
may potentially increase the antitumor efficacy of TNF (18, 19).
Second, the presence and amounts of such cytokines can be tailored
by using inducible systems to optimize spatiotemporal expression,
and further limit cytokine-dependent systemic counterregulatory
and toxic effects.
Our characterization of the system demonstrates that the anti-
cancer activity of TNF-expressing cells in vivo is dependent on the
number of cells administered, rather than on the amount of TNF
released per cell (Fig. 2 A and C). In fact, we show here that TSA,
B16-F10, or LLC cells expressing widely different levels of TNF
(from 0.015 to 153 fg per cell per day) induced comparable delays
in tumor growth rates. We hypothesize that single cells, even low
TNF-producing cells can locally release an amount of TNF that is
sufficient to cause endothelial damage in tumor blood vessels. In-
creasing the numbers of administered cells, regardless of the ab-
solute amounts of secreted TNF per cell, are expected to be
paralleled by increased numbers of affected vascular loci, and
damage of even a single endothelial cell can theoretically lead to
impaired perfusion of an entire capillary that may exponentially
affect large tumor areas. In support of our hypothesis, we observed
apoptosis of endothelial cells in s.c. tumors as early as 1 d after i.v.
injection of TNF-expressing cells that was sequentially followed by
marked apoptosis of tumor cells after 2 d. This putative mechanism
is further confirmed by the finding that TNF-expressing cells inhibit
the growth of preexisting tumors when injected i.v., but not when
injected s.c. in the contralateral flank. This suggests the antitumor
activity of TNF-expressing cells presumably requires homing to the
tumor from the circulation, a key event to induce vascular endo-
thelial damage leading to tumor cell death.
Cancer cells engineered to express antitumor agents reduced
both primary tumor and metastatic colony growth, but did not
abrogate them. Efficacy of our system, however, could be improved
by combination therapy. For example, a significant increase of the
response to targeted TNF was found with either chemotherapy or
immunotherapy, both active and adoptive (20–22). Remarkably,
strong synergistic effects were achieved (including tumor eradica-
tion), compared with the modest reduction induced by targeted
TNF alone (23). Combinatorial therapy could also improve the
treatment of larger cancer lesions due to their density in vascu-
larization. Furthermore, metastatic derivatives showed a superior
ability to infiltrate parental tumors (1); therefore, engineering











highly metastatic cells may further improve their homing properties
and thus efficacy.
Considering the multiple functions of TNF (11), other mecha-
nisms might perhaps contribute to the antitumor effects of TNF-
expressing cells, such as direct cytotoxic effects or activation of
inflammatory and immune responses. However, we did not observe
any detectable effect on the growth and vitality of tumor cells by
tumor-cell–released TNF in vitro. Furthermore, analysis of im-
mune cell infiltrates revealed only a modest and not statistically
significant increase in CD4+ T cells upon treatment of s.c. TSA
tumors with TNF-expressing cells. These data confirm that cell
toxicity and inflammation are not likely to be crucial in TNF-
mediated inhibition of tumor growth in our experimental models.
Interestingly, mice injected s.c. with syngeneic TNF-expressing cells
were unable to develop tumors after subsequent challenges with
corresponding parental tumor cells. Although further experiments
will be needed to clarify this observation, one may speculate that
TNF expression causes increased immunogenicity and consequent
rejection of cancer cells. Concomitantly or alternatively, TNF-
expressing cells may have induced a long-lasting effect at the re-
gional injection site, which negatively impacted VEGF secretion
and angiogenesis to create a microenvironment that is no longer
permissible for tumor growth.
Finally, although cancer cells may represent a uniquely effective
delivery system for cytokines, important safety concerns must be
addressed before embarking on translational applications of this
work. An obvious concern is the risk that injected tumor cells could
give rise to new neoplastic lesions. Our characterization of the
tumorigenic and metastatic properties of TNF-expressing tumor
cells showed that injection of these cells into the circulation of
syngeneic mice, results in lung colonies, even though their tumor-
igenic and metastatic potential is markedly reduced compared with
parental cells. Furthermore, we report that systemic administration
of TNF-expressing cells to nonsyngeneic mice inhibited tumor
growth to about the same extent as the administration in syngeneic
mice, but in the complete absence of lung colonies, representing a
further improvement toward addressing the safety concerns. In this
case, an immune response likely caused the rejection of the non-
syngeneic cells within a few days, after a period that was sufficient
to exert their therapeutic effect. To increase the safety of this ap-
proach, and to circumvent any possible escape from the immune
system, cytokine-expressing tumor cells could be further engi-
neered to express immunogenic proteins and/or inducible suicide
genes (24, 25) with the aim of clearing the injected tumor cells after
the desired therapeutic effect is achieved. The observation that the
antitumor effects of TNF-releasing cells are similar in non-
syngeneic and syngeneic systems, at least in mice, suggests that a
common tumor cell line might be effective in different individuals.
This may allow the production of highly standardized and finely
controlled cells under good manufacturing conditions and with
precise protocols for future translational applications. Extensive
studies, however, will be required to demonstrate that the safety
issues of this delivery system can be managed in a clinical context.
Materials and Methods
Animal Models. Animal studies were approved by the Institutional Animal
Care and Use Committee of The University of Texas, MD Anderson Cancer
Center and are described further in SI Materials and Methods.
Cell Lines, Recombinant TNF, and Antibodies. Murine TSA mammary adenocarci-
noma cells (derived from BALB/c mice) were provided by Giulia Casorati (San
Raffaele Institute, Milan). The following cell lines were purchased from the
American Type Culture Collection: murine B16-F10melanoma,murine Lewis lung
carcinoma (both on a C57BL/6 strain), and human EAhy.926 endothelial cells.
Murine TNF was prepared by recombinant DNA technology and purified from
Escherichia coli cell extracts as described (12). Rabbit polyclonal anti-cCasp3 and
CD31 antibodies were purchased from Cell Signaling Technology.
Preparation of TNF-Expressing Tumor Cells. The coding region formurine TNF in
the pET-11b-tnf plasmid (12) was PCR amplified and inserted into the pLenti6/
V5 DEST Gateway Vector (Invitrogen) with the In-fusion cloning kit (Clontech).
The resultant pLenti-mtnf vector was transfected into HEK-293FT cells (Invi-
trogen) by incubation with Lipofectamine 2000 (Invitrogen). Culture medium
was replaced after overnight incubation at 37 °C in 5% CO2, and viral particles
were collected 24 and 48 h later and pooled. Supernatants were tested for viral
particle content by using Lenti-X GoStix (Clontech). TSA, B16-F10, or LLC cells
were transduced with 1–2 mL of virus-containing supernatant. Tumor cells
expressing low levels of TNF were selected in the presence of 3 μg/mL blasticidin
(Sigma-Aldrich). Derived cell lines were named TSAtnf low, B16-F10tnf low, or
LCCtnf low. Cells expressing higher levels of TNF were selected in the presence of
50 μg/mL blasticidin (for TSA) or by reinfection with the lentivirus (for B16-F10,
LCC). These cells were designated as TSAtnf, B16-F10tnf, or LCCtnf.
Additional materials and methods are presented in SI Materials and
Methods.
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SI Materials and Methods
Animal Models.Animal studies were approved by the Institutional
Animal Care andUse Committee of TheUniversity of Texas, MD
Anderson Cancer Center. For the s.c. xenograft model, BALB/c
or C57BL/6 mice (8-wk-old females, Charles River Laboratories)
were injected into the flank with either the parental (i.e., non-
transduced with pLenti-mTNF) or TNF-expressing tumor cells.
Unless stated otherwise, BALB/c mice were injected with 4 × 105
TSA or TSAtnf cells per mouse, and C57BL/6 mice were injected
with 4 × 105 B16-F10 or B16-F10tnf cells per mouse, or with 8 ×
105 LLC or LLCtnf cells per mouse. Tumor growth was moni-
tored every 2–3 d by measuring tumor sizes with a caliper. For
the metastatic model, mice were injected i.v. into the tail vein
(same mouse strain/cell line combination as for the s.c. model)
with 7 × 104 TSA or TSAtnf cells per mouse, 1.2 × 105 B10-F16,
or B16-F10tnf cells per mouse, or with 3 × 105 LCC or LLCtnf
cells per mouse. After 14 (TSA), 11 (B16-F10), or 28 (LCC)
days, mice were killed. Lungs were harvested, weighed, and the
number of pulmonary colonies counted with a stereomicroscope.
For the intervention trials, the following numbers of TNF-ex-
pressing cells were injected i.v. when primary s.c. tumors reached
50 mm3 or after 7 d from tumor onset for the following meta-
static models: TSAtnf, 7 × 105 cells per mouse; B16-F10tnf, 2 ×
105 cells per mouse; and LLCtnf, 3 × 105 cells per mouse. Other
specific mouse strain/cell line combinations and numbers of in-
jected cells are detailed in Results.
Detection of pLenti-mTNF-Transduced Cells in the Blood Circulation
and in Tumors. To track circulating TNF-expressing cells, mice were
bled 1, 2, and 4 d after i.v. injection of TNF-expressing cells. Aliquots
of blood (100 μL) were collected in heparinized tubes lysed with Red
Blood Cell Lysis Solution (Promega) and DNA was extracted using
the DNeasy Blood and Tissue kit (Qiagen). To assess tumor homing
of TNF-expressing cells, DNA was directly extracted from tumor
masses using the same protocol 4 d after i.v. injection. In both cases,
DNA was subjected to PCR with the following primer pair: 5′-
TGGAATTCTGCAGATATCAAC-3′ and 5′-CCGGTACGCG-
TAGAATCG-3′, designed to specifically amplify a pLenti-mTNF
sequence that is not present in the murine genome. PCR products
were analyzed by 2% (wt/vol) agarose gel electrophoresis in the
presence of ethidium bromide, and band intensities were quantified
using Photoshop CS4 software (Adobe).
Immunofluorescence Analysis of Tumor and Endothelial Cell Apoptosis.
Cell apoptosis in TSA, B16-F10, and LLC tumors was quantified by
immunofluorescence analysis of cCasp3 immunoreactivity from
frozen, 10-μm-thick tumor sections. Tissue sections were fixed
with 2% (vol/vol) paraformaldehyde in PBS and blocked with 5%
(vol/vol) normal goat serum, 1% BSA, and 0.3% Triton X-100 in
PBS. Sections were incubated with rabbit polyclonal anti-cCasp3 in
1% normal goat serum, 1% BSA, 0.3% Triton X-100 in PBS,
followed by goat anti-rabbit IgG Cy3 antibody (Jackson Immuno-
Research). Black/white images were acquired using an Olympus
IX70 inverted fluorescence microscope/MagnaFire software and
analyzed using Photoshop CS4 software (Adobe). At least 20 im-
ages per tumor were acquired (three tumors per group). Positive
cCasp3 areas were selected with the Photoshop “magic wizard”
tool and the total number of positive pixels (ppT) for each image
was calculated. To calculate the percentage of apoptotic areas in a
tumor section, ppT was divided by the total number of pixels per
tumor section. Similarly, to assess endothelial cell apoptosis, sec-
tions were incubated with anti-cCasp3 and CD31 antibodies (Ab-
cam), followed by goat anti-rabbit Alexa Fluor 488 and anti-rat
Alexa Fluor 546 (Invitrogen), respectively. Quantification of apo-
ptotic cells was performed on entire tumor sections. Scores were
assigned to each section based on the number of cCasp3/CD31
double positive cells: 0 (0 vessels), 1 (1–10 vessels), 2 (11–20 ves-
sels), 3 (21–30 vessels), 4 (31–40 vessels), and 5 (>41 vessels).
Titration of TNF in Cell Supernatants by EAhy.926 Cytolytic Assay. The
amounts of TNF secreted by the pLenti-mTNF–transduced cells
were quantified in cell supernatants by a cytolytic assay. Thirty
thousand EAhy.926 cells were plated per well in a 96-well flat-
bottom plate in complete medium and incubated overnight at
37 °C, 5% (vol/vol) CO2. Fifty microliters of actinomycin-D (posi-
tive control, 3 μg/mL final concentration in complete medium),
serial dilutions of recombinant murine TNF (standard curve, 0.6–
1500 pg/mL final concentration in complete medium), or serial
dilutions of supernatants from the TNF-producing cells were added
to each well, followed by 24-h incubation at 37 °C, 5% (vol/vol)
CO2. Cells were washed with PBS, fixed with 4% (vol/vol) para-
formaldehyde [15 min, room temperature (RT)] and stained with
0.5% crystal violet in 20% (vol/vol) methanol (10 min, RT). Plates
were extensively washed with tap water before measuring the ab-
sorbance at λ = 570 nm (EC50: 150 ± 50 fg/mL TNF; detection limit:
6 fg/mL TNF).
Tumor Cell Cytotoxicity Assay. TSA (6 × 104 cells per well), B16-
F10 (4 × 104 cells per well), or LLC (6 × 104 cells per well) were
plated in a 96-well flat-bottom plate and incubated in complete
medium for 24 h at 37 °C, 5% vol/vol CO2. Murine TNF (0–500
ng/mL) was added to cells in complete medium and incubated
for 24 h at 37 °C, 5% vol/vol CO2. Viable cells were stained with
crystal violet, the absorbance was measured at λ = 570 nm.
Tumor Cell Proliferation Assay. TSA (1.8 × 103 cells per well), B16-
F10 (15 × 103 cells per well), or LLC (7.5 × 103 cells per well)
cells were seeded per well of 96-well plates and incubated in
complete medium at 37 °C, 5% (vol/vol) CO2. Viable cells were
evaluated at day 0 and day 3 by staining with 5 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution
(MTT, 10 μL per well, 2 h at 37 °C). Absorbance was measured
at λ = 570 nm in a microtiter plate reader. The proliferation
index of each cell population was calculated by dividing the
absorbance values at day 3 by those at day 0.
Tumor Cell Irradiation. TSAtnf cells were plated in a 10-cm dish
(1 × 107 cells per plate) and irradiated at 35 Gy. Cells were further
analyzed for cell proliferation and TNF production as reported.
FACS Analysis of Immune Cells Within Tumors.The number of tumor-
infiltrating CD45+ lymphatic and myeloid cells was analyzed by
FACS. Tumors were excised, mechanically disaggregated with a
70-μm cell strainer, resuspended in 2% (vol/vol) FCS in PBS,
and incubated for 15 min with antibodies as follows: anti-CD45
PE-Cy 7, anti-CD4 PE, anti-CD8b APC, anti-CD11c FITC or
CD45 PE-Cy 7, anti-CD11b PerCP-Cy 5.5, and anti-Gr1 FITC
(BD Pharmingen). Samples were analyzed with an LSRII FACS
equipped with Diva software.
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Fig. S1. Intervention trial: intravenous, but not s.c. administration of TSAtnf cells reduces the growth of established s.c. TSA tumors. Mice were injected s.c.
with TSA cells (4 × 105 cells per mouse). After 7 d, mice were injected with TSAtnf cells (4 × 105 cells per mouse) s.c. (A) or i.v. (B). Two experiments were
performed (n = 3 each). Experimental schedule and tumor volume (mean ± SE) of one representative experiment is shown. *P < 0.05 by t test, two tailed.
Fig. S2. Irradiation reduces TSAtnf cell antitumor activity. (A) Amount of bioactive TNF released in the supernatant by irradiated TSAtnf at days 1, 2, and 3 postirradiation, as
measured by a cytolytic assay (mean ± SE). Experiments were performed in triplicate and repeated two times. Proliferation of irradiated TSAtnf cells as evaluated by MTT
staining (n = 4, mean ± SE). Two experiments were performed, and one representative experiment is shown. (B) Effect of i.v. administration of irradiated (Irr) or nonirradiated
TSAtnf cells (3 ×105) on the growth of TSA tumors implanted s.c. in syngeneic mice. Tumor volumes (mean ± SEM) are shown (n= 5). *P < 0.05; **P < 0.01 by t test, two tailed.
Fig. S3. I.v. administration of TSAtnf cells does not affect recruitment of subpopulations of CD45+ cells to the tumors. Evaluation of CD45+ immune infiltrating
cells (Gr1−CD11b+, Gr1+CD11b+, Gr1+CD11b−, CD11c+, CD4+, and CD8+) by FACS. Results are represented as percentage of the amount of CD45+ (n = 4–5). None
of the markers were significantly different following i.v. administration of TSAtnf in comparison with parental TSA cells.
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